Menotrophin

Adult: Pretreatment with hCG stimulates spermatogenesis. Thereafter, initiate menotrophin at 75 or 150 IU 2 or 3 times weekly via SC or IM inj in combination with hCG. Continue treatment for at least 3 or 4 months.

Adult: For cases in women (including polycystic ovarian disease) who are unresponsive to clomifene citrate: Begin therapy within the 1st 7 days of the menstrual cycle. Initially, 75-150 IU daily via SC or IM inj; maintained for at least 7 days. Adjust subsequent doses according to individual response (based on clinical monitoring including ovarian ultrasound alone or combined with serum estradiol level measurement); dose must be adjusted in increments of 37.5 IU (up to Max of 75 IU) at least every 7 days. Max: 225 IU daily. If patient fails to adequately respond after 3 or 4 weeks, abandon that cycle and recommence treatment at a higher initial dose than the abandoned cycle. If optimal response is obtained, hCG may be given 1 day after the last menotrophin dose. If an excessive response is attained, discontinue treatment and withhold hCG administration. Further patient instructions and monitoring may be required based on individual ovarian response. Dosage and treatment duration recommendations may vary among individual products and between countries. Refer to local detailed product guidelines.

Adult: In protocol using down-regulation with gonadotrophin-releasing hormone (GnRH) antagonist, begin menotrophin therapy on day 2 or 3 of the menstrual cycle. In protocol using down-regulation with GnRH agonist, initiate menotrophin therapy approx 2 weeks after the start of the agonist treatment. Initially, 150-225 IU daily via SC or IM inj for at least the 1st 5 days of therapy. Adjust subsequent doses according to individual response (based on clinical monitoring including ovarian ultrasound alone or combined with serum estradiol level measurement); dose must be adjusted in increments of up to 150 IU. Max: 450 IU daily. Max treatment duration: 20 days. When a suitable number of follicles reached an appropriate size, hCG may be given to induce final follicular maturation in preparation for oocyte retrieval. If an excessive response is attained, discontinue treatment and withhold hCG administration. Further patient instructions and monitoring may be required based on individual ovarian response. Dosage and treatment duration recommendations may vary among individual products and between countries. Refer to local detailed product guidelines.